-
Cipla reaches patent litigation settlement with Celgene on generic Revlimid
Celgene has agreed to provide Cipla with a license to its patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the United States beginning on a confidential date some time after March 2022.